tbuckley/cabot-search huggingface dataset:
Tracheo-Bronchoscopy, Esophagoscopy and Gastroscopy.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
National Conference on Advances in the Care of the Child With Cancer
Journal: JNCI Journal of the National Cancer Institute (1985)

Journal Article National Conference on Advances in the Care of the Child With Cancer Get access JNCI: Journal of the National Cancer Institute, Volume 74, Issue 2, February 1985, Page 541, https://doi.org/10.1093/jnci/74.2.541-e Published: 01 February 1985
From the Centers for Disease Control and Prevention. Dengue fever at the US-Mexico border, 1995-1996
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Officials of the Association 1977-1978
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OP0062 Safety and Efficacy of Etanercept in Children with the JIA Categories Extended Oligoarthritis, Enthesitis Related Arthritis and Psoriasis Arthritis
Authors: D. Windschall, G. Horneff
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The approval of the recombinant TNF receptor fusion protein etanercept for the treatment of the JIA categories resistant extended Oligoarthritis (ExOA), enthesitis related arthritis(ERA) and psoriasis arthritis (PSA) was actually added to the German approval for the treatment of resistant polyarticular juvenile arthritis. <h3>Objectives</h3> To evaluate the efficacy and safety in the additional JIA category patients treated with Etanercept. <h3>Methods</h3> Baseline demographics, clinical characteristics and disease activity parameters have been documented. Efficacy was determined using the PedACR 30/50/70 response criteria and the JADAS 10 activity score. Safety assessments were based on adverse events reports from the primary responsible physician. <h3>Results</h3> Until December 31st, 2012 238 patients with ERA, 315 patients with ExOA and 127 patients with PSA were admitted to the registry. Especially the percentage of patients with ERA was increasing over the last decade. Patients in all additional approved indications and categories showed significant improvement in most parameters of disease activity between baseline and last observation. All mentioned categories started with a mean baseline JADAS 10 activity score over 15 ( RF positive 19,3; RF negative 18,3; ExtOA 17,5; ERA 16,0 and PSA 15,2) and developed significant response to the treatment after 3 months (RF positive 8,2 ; RF negative 7,25; ExtOA 5,4; ERA 4,3; PsA 4,8 ) and after 24 months (RF positive 4,7; RF negative 5,1; ExtOA 2,6; ERA 4,0 and PSA 4,8). Serious and nonserious adverse events rates seem similar in all JIA categories, especially with respect to infections. However, rate of uveitis flares were higher in PSA (3.3/100Patyears[95%CI 1.6-6.7], ExtOA (2.8[1.8-4.3]) and ERA (2.7[1.5-4.9]) than in RF negative (1.3[0.8-2.2]) or RF positive (0.3[0.05-0.7]). Chronic inflammatory bowel disease occurred more frequently in ExtOA (0.73[95%CI 0.3-1.7], ERA (0.49[0.1-1.8]) and PSA (0.47[0.09-0.89]) than in RF negative (0.26[0.1-0.55]) or RF positive (0[0-0.51]). <h3>Conclusions</h3> These data emphasises that administration of etanercept in patients with the JIA categories resistant extended oligoarthritis, enthesitis related arthritis and psoriasis arthritis is safe and very efficacious in children. Attention should be payed to the occurrence of extraarticular autoimmunopathies like uveitis flares and chronic inflammatory bowel disease. <h3>Disclosure of Interest</h3> D. Windschall Grant/research support from: Pfizer, G. Horneff Grant/research support from: Pfizer, Abbott, Roche
From the Centers for Disease Control and Prevention. Effectiveness of rollover protective structures for preventing injuries, agricultural tractors
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer.
Authors: Toni K. Choueiri, Noah M. Hahn, Sumanta Kumar Pal, Ajjai Shivaram Alva, Robert Dreicer, Alexander Starodub, Guru Sonpavde, Jean H. Hoffman-Censits, Joel Picus, Arjun Vasant Balar, Elizabeth A. Guancial, Meredith M. Regan, Cindy Jacobs, Patricia S. Stewart, Jonathan E. Rosenberg
Journal: Journal of Clinical Oncology (2014)

TPS4593^ Background: Heat shock protein 27 (Hsp27) is over-expressed in many cancers including bladder, lung, prostate, and breast. Increased Hsp27 has been associated with inhibition of chemotherapy-induced apoptosis, increased tumor cytoprotection, and development of treatment resistance. OGX-427 (Apatorsen) is an antisense oligonucleotide designed to bind Hsp27 mRNA, inhibiting production of the Hsp27 protein. Inhibition of Hsp27 has been shown to increase apoptosis, inhibit tumor growth, and sensitize tumor cells to chemotherapy in a variety of malignancies, including urothelial cancer. Results of preclinical and phase 1 studies suggest that addition of apatorsen to chemotherapy is well tolerated and may improve treatment efficacy. Borealis-2 is a randomized, multicenter, phase 2 study of apatorsen in combination with docetaxel (DOC) vs. DOC alone in locally advanced/metastatic bladder cancer patients who received at least one line of prior platinum-based therapy. The primary objective is to evaluate overall survival. Secondary objectives include comparisons of safety and tolerability, disease response, and serum levels of Hsp27 and other pathway-related proteins. Associations between clinical outcomes, levels of Hsp27 and other proteins, and circulating tumor cells will be evaluated. Methods: Patients (N=200) are randomized in a 1:1 ratio following stratification (time from prior systemic chemotherapy; Bellmunt criteria). Up to 2 prior systemic therapies are allowed. Treatment-arm patients receive three loading doses of apatorsen (600 mg) followed by up to ten 21-day treatment cycles (apatorsen 600 mg on Days 1, 8, and 15 and DOC 75 mg/M2 IV on Day 1). Control-arm patients receive DOC 75 mg/M2 IV on Day 1 of each cycle. Treatment may continue until disease progression, unacceptable toxicity, completion of ten cycles, or patient withdrawal. Patients who discontinue DOC due to toxicity after ≥2 cycles and do not have disease progression may receive maintenance therapy with apatorsen. One interim futility analysis will be performed. The trial will not be stopped early based on efficacy. Clinical trial information: NCT01780545.
Mind Reading
Authors: Elissa Ely
Journal: New England Journal of Medicine (2004)

I was called in to see a man I did not know. No one knew him. His usual doctor was on vacation, and the social worker who paged me was covering for another social worker.“Can't it wait a week?” I asked. The patient had been in the hospital for three years without a psychiatric evaluation.“I don't think so,” the social worker said. “He hasn't taken food or fluids for two days. But,” she added, trying to encourage me, “he does take every pill.”The consultation question was the patient's competence. Did he mean to kill himself? The chart . . .
Small-bowel endoscopy
Authors: K. Mönkemüller, M. Bellutti, P. Malfertheiner
Journal: Endoscopy (2007)

Capsule endoscopy and double-balloon enteroscopy (DBE) have become the methods of choice for evaluation of small-bowel disorders. The number of abstracts presented at this year’s Digestive Disease Week (DDW) is testament to the fact that there is still considerable ongoing research interest in the field of small-bowel endoscopic methods. A total of 135 scientific contributions evaluating capsule endoscopy or DBE were presented this year, 71 of which concerned capsule endoscopy and 53 DBE, with 11 presentations comparing the two techniques. Furthermore, other data have shown that these endoscopic methods can also be used for diseases outside the small bowel: capsule endoscopy is being investigated as a potential method to screen for Barrett’s esophagus and esophageal varices and to evaluate the colon; and DBE has been found to be useful for examining the colon in patients with previously failed colonoscopy, for the placement of a gastrostomy in patients undergoing bariatric surgery, and for performing endoscopic retrograde cholangiopancreatography (ERCP) in patients with a Roux-en-Y anastomosis ([Fig. 1]). In this review we will summarize the research presented at this year’s DDW, focusing on diseases of the small bowel.
Incorrect Information in Reply Letter
Authors: Isabella Fogh, Ammar Al-Chalabi, John Powell
Journal: JAMA Neurology (2014)

estimated the summary heritability excluding the overlapping data set.We still achieve a similar result (h 2 , 21.4%; 95% CI, 19.9-23.0;SE, 0.8%).In conclusion, we are pleased that the study of Keller et al 1 has validated our previous results when using the same assumptions.This demonstrates that the methods used to estimate the additive genetic variance due to common variation are reliable.However, contrary to the assertion of Keller et al, 1 the heritability of ALS is highly dependent on the estimated prevalence; therefore, heritability should be presented for a range of plausible values for prevalence.This approach has been applied to estimates for the heritability of ALS from family data obtained from a research register. 4 For the same range of prevalences, heritability estimated from family data is consistently greater than values for heritability that we have estimated using common variation, indicating that there are potentially rarer variants not captured by commercial genotyping arrays that contribute to the risk for ALS.
PUERPERAL FEVER AND THE MONUMENT TO SEMMELWEIS.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Companion
Authors: Richard F. Herndon
Journal: JAMA (1984)

<h3>To the Editor.—</h3> The patient's companion is common in office practice. I thought the companion (someone who accompanies the patient to the office) relevant to management, so I interviewed them for six months to investigate the phenomenon. One hundred six consecutive companions were interviewed. These interviews involved an office patient volume of 1,240 visits (incidence, 8.6%). Reports from ambulatory psychiatry practice have described the companion<sup>1,2</sup>at an incidence of up to 45%. In medical office practice, the companion is obvious as is his intent, but special illustrations are helpful. <h3>Credibility—</h3> The companion gives credence to a complaint. A 74-years-old woman came with her companion, her daughter. The patient had been seen four times before with a "swimming" feeling in her head. Before the visit her daughter called, stating that her mother had a roaring noise in her left ear that she, the daughter, could hear. Although I could not
The newly licensed hepatitis B vaccine. Characteristics and indications for use
Authors: S. Krugman
Journal: JAMA (1982)

The inactivated hepatitis B vaccine that was licensed in November 1981 will be distributed for general use later this year. Extensive studies have confirmed the safety, immunogenicity, and remarkable efficacy of this vaccine for the prevention of acute hepatitis B disease, asymptomatic infection, and the chronic hepatitis B carrier state. The vaccine is recommended for immunization of infants, children, and adults who are considered to be at increased risk of contracting hepatitis B infection. These population groups include medical, dental, laboratory, and other health care personnel, selected patients (eg, hemodialysis, thalassemia), clients and staff of institutions for the mentally disabled, homosexually active males, intimate contacts of carriers, users of illicit drugs, infants in high-risk areas, and other high-risk groups. The availability and appropriate use of the newly licensed hepatitis B vaccine should enable physicians to prevent a serious cause of acute and chronic liver disease. (<i>JAMA</i>1982;247:2012-2015)
Horizon
Authors: John Davis
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Head Injuries
Authors: Manucher Javid
Journal: New England Journal of Medicine (1974)

IN the United States, approximately 50,000 lives are lost each year as a result of motor vehicle accidents. Head injuries occur in more than two thirds of all such accidents. Sixty per cent of deaths from brain injuries occur during the first 24 hours. To decrease the morbidity and mortality rate, improved emergency management is essential.First AidAt the Scene of the AccidentSince emergency care at the scene of the accident is not carried out by physicians, the education of paramedics in emergency care of the injured is essential. Cerebral anoxia is the most frequent cause of death; . . .
Effects of a Multidimensional Anabolic Steroid Prevention Intervention
Authors: Linn Goldberg
Journal: JAMA (1996)

<h3>Objective.</h3> —To test a team-based, educational intervention designed to reduce adolescent athletes' intent to use anabolic androgenic steroids (AAS). <h3>Design.</h3> —Randomized Randomized prospective trial. <h3>Setting.</h3> —Thirty-one high school football teams in the Portland, Ore, area. <h3>Participants.</h3> —Seven hundred two adolescent football players at experimental schools; 804 players at control schools. <h3>Intervention.</h3> —Seven weekly, 50-minute class sessions were delivered by coaches and student team leaders, addressing AAS effects, sports nutrition and strength-training alternatives to AAS use, drug refusal role play, and anti-AAS media messages. Seven weight-room sessions were taught by research staff. Parents received written information and were invited to a discussion session. <h3>Main Outcome Measures.</h3> —Questionnaires before and after intervention and at 9- or 12-month follow-up, assessing AAS use risk factors, knowledge and attitudes concerning AAS, sports nutrition and exercise knowledge and behaviors, and intentions to use AAS. <h3>Results.</h3> —Compared with controls, experimental subjects at the long-term follow-up had increased understanding of AAS effects, greater belief in personal vulnerability to the adverse consequences of AAS, improved drug refusal skills, less belief in AAS-promoting media messages, increased belief in the team as an information source, improved perception of athletic abilities and strength-training selfefficacy, improved nutrition and exercise behaviors, and reduced intentions to use AAS. Many other beneficial program effects remained significant at the long-term follow-up. <h3>Conclusions.</h3> —This AAS prevention program enhanced healthy behaviors, reduced factors that encourage AAS use, and lowered intent to use AAS. These changes were sustained over the period of 1 year. Team-based interventions appear to be an effective approach to improve adolescent behaviors and reduce drug use risk factors.
Abstract 741: Atrial Fibrillation Begets Atrial Fibrillation: Acute Autonomic Remodeling Leads to Enhanced Inducibility for Atrial Fibrillation
Authors: Zhibing Lu, Benjamin J Scherlag, Guo-Dong Niu, Jiaxiong Lin, Muhammad Ghias, Ralph Lazzara, Warren M Jackman, Sunny S Po
Journal: Circulation (2007)

Introduction: There have been many forms of remodeling reported to play a role in the concept of “atrial fibrillation (AF) begets atrial fibrillation.” The role of intrinsic cardiac nervous system (ICNS) in this remodeling process was evaluated in this study. Methods: Continuous rapid pacing (1200 bpm, 2× threshold, TH) was performed at the left atrial appendage to maintain AF. Group 1 (N=7): 6-hours of pacing followed by ganglionated plexi (GP) ablation, both left and right side; Group 2 (N=7): GP ablation followed by 6-hours of pacing. At 2x and 10x TH, the effective refractory period (ERP) and window of vulnerability (WOV), i.e., longest-shortest coupling of premature stimulus which induced AF in milliseconds (ms), were measured at the left atrium, right atrium and pulmonary veins (PVs) every hour during the 6-hours of pacing before and after GP ablation. Results: In group 1 (rapid pacing with GP intact) ERP progressively shortened in the first two hours and then stabilized both at 2×TH and 10×TH (Figure 1A ), however, WOV progressively widened throughout the time period (Figure 1B ). After GP ablation, ERP was significantly longer than prior to ablation and AF could not be induced (WOV=0, p&lt;0.01) at any pacing site at either 2×TH or 10×TH (Figure 1B ). In group 2 (initial GP ablation), ERP exhibited a slightly increasing trend as the pacing time increased. AF could not be induced in 6/7 dogs during the 6-hour pacing, and was inducible in 1/7 with a cumulative WOV of only 10 ms. Conclusion: The ICNS is crucial for the process of “AF begets AF” in the acute stages of remodeling by rapid atrial pacing.